Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی

Studies and guidelines: Testicular cancer

9 items with a structured summary · Testicular cancer: the complete guide

Clinical guideline

Fertility Preservation in People With Cancer: ASCO Guideline Update

JCO · 2025
166 studiesEvidence base
Summary
Clinical guideline

European Association of Urology Guidelines on Testicular Cancer: 2023 Update

Eur Urol · 2023
Good 96%, intermediate 89%, poor 67%5-year overall survival in metastatic non-seminoma (IGCCCG update)
Summary
Clinical guideline

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Clinical Chemistry · 2008
AFP, hCG and LDHTesticular cancer
Summary
Observational study

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

J Clin Oncol · 2021
96% (vs 92% in the original classification)5-year overall survival, good prognosis
Summary
Observational study

Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance

J Clin Oncol · 2015
221 patients (19%)Relapse in stage I non-seminoma
Summary
Clinical trial · Phase 3

Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214)

J Clin Oncol · 2011
94.7% (carboplatin) vs 96.0% (radiotherapy)5-year relapse-free rate
Summary
Observational study

High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors

N Engl J Med · 2007
116 of 184Complete remission without relapse (all patients)
Summary
Clinical trial · Phase 3

Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a ‎3-‎ or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council

J Clin Oncol · 2001
90.4% vs 89.4%Projected 2-year PFS: 3 vs 4 cycles
Summary
Clinical trial

Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

N Engl J Med · 1987
74% (vinblastine regimen) vs 83% (etoposide regimen)Becoming disease-free (244 evaluable patients)
Summary